Non-interventional Prospective Observational Survey to Describe EGb 761 (Tanakan) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders.
Phase of Trial: Phase IV
Latest Information Update: 03 Jul 2015
At a glance
- Drugs EGb 761 (Primary)
- Indications Cognition disorders
- Focus Therapeutic Use
- Acronyms TAYPES
- Sponsors Ipsen
- 30 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 04 Mar 2015 Planned End Date changed from 1 May 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
- 04 Mar 2015 Planned primary completion date changed from 1 May 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.